[Bioavailability of two slow-release formulations of verapamil].
The bioavailability of 2 slow release formulations (test (P) and reference (R)) of verapamil was investigated in a study with a randomised cross over design, 20 healthy male subjects were included. The mean peak plasma concentration (36.1 +/- 13.1 ng/ml) of the test preparation was reached after 3.75 +/- 0.8 h. The control preparation (R) produced peak values of 34.4 +/- 8.1 ng/ml after 5.6 +/- 3.1 h. MRT (P) was 17.6 +/- 8.2 h and for (R) was 21.1 +/- 7.5 h after (R). The 95-%-confidence interval of the two preparations differed by more than 20%. The release rate of (P) is slower than that of (R).
Keller-Stanislawski
B
B
Abtielung für Klinische Pharmakologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Rietbrock
N
N
D000328:Adult; D001682:Biological Availability; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D011897:Random Allocation; D014700:Verapamil / Q000008:administration & dosage / Q000493:pharmacokinetics*
D003692:Delayed-Action Preparations; D014700:Verapamil
Bioverfügbarkeit von zwei Verapamil-Zubereitungen mit verzögerter Freisetzung.